Fasting State
7
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (7)
Neurocognitive Effects of Meal Timing in a One-Meal-a-Day Regimen
Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fasting Condition
Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition
Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition
Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition
Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg Under Fasting Condition
Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting Condition